| The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation SD Reiff, R Mantel, LL Smith, JT Greene, EM Muhowski, CA Fabian, ... Cancer discovery 8 (10), 1300-1315, 2018 | 146 | 2018 |
| IGF1R-and ROR1-specific CAR T cells as a potential therapy for high risk sarcomas X Huang, H Park, J Greene, J Pao, E Mulvey, SX Zhou, CM Albert, F Moy, ... PloS one 10 (7), e0133152, 2015 | 120 | 2015 |
| PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression S Dong, BK Harrington, EY Hu, JT Greene, AM Lehman, M Tran, ... The Journal of clinical investigation 129 (1), 122-136, 2019 | 58 | 2019 |
| Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia MK McKenna, SK Noothi, SS Alhakeem, KZ Oben, JT Greene, R Mani, ... Blood, The Journal of the American Society of Hematology 131 (26), 2943-2954, 2018 | 15 | 2018 |
| Regulation of myeloid-cell activation JT Greene, BF Brian IV, SE Senevirathne, TS Freedman Current opinion in immunology 73, 34-42, 2021 | 13 | 2021 |
| Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling JT Greene, R Mani, R Ramaswamy, F Frissora, M Yano, K Zapolnik, ... Blood Advances 3 (8), 1255-1266, 2019 | 9 | 2019 |
| The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation. Cancer Discov. 2018; 8 (10): 1300–1315, doi: 10.1158/2159-8290 SD Reiff, R Mantel, LL Smith, JT Greene, EM Muhowski, CA Fabian CD-17-1409.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 9 | |
| A dominant function of LynB kinase in preventing autoimmunity BF Brian IV, ML Sauer, JT Greene, SE Senevirathne, AJ Lindstedt, ... Science advances 8 (16), eabj5227, 2022 | 3 | 2022 |
| The BTK inhibitor ARQ531 targets ibrutinibresistant CLL and richter transformation. Cancer Discov.(2018) 8: 1300–15. doi: 10.1158/2159-8290 SD Reiff, R Mantel, LL Smith, JT Greene, EM Muhowski, A Fabian CD-17-1409, 0 | 3 | |
| Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitors DM Rasmussen, MM Semonis, JT Greene, JM Muretta, AR Thompson, ... Elife 13, RP95481, 2024 | 2 | 2024 |
| ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer SY Bae, HE Bergom, A Day, JT Greene, ZE Sychev, G Larson, E Corey, ... Frontiers in Endocrinology 14, 1093332, 2023 | 1 | 2023 |
| Role of Prostate apoptosis response-4 tumor suppressor in the survival and growth of Chronic Lymphocytic Leukemia SK Nooti, MK McKenna, FW Frissora, BW Gachuki, SS Alhakeem, ... Blood, The Journal of the American Society of Hematology 126 (23), 1731-1731, 2015 | 1 | 2015 |
| Abstract PR02: Lyn kinase regulates myeloid-cell responses to mammary tumors JT Greene, BF Brian, A Bapat, TS Freedman Cancer Immunology Research 11 (12_Supplement), PR02-PR02, 2023 | | 2023 |
| Primary infection with Zika virus provides one-way heterologous protection against Spondweni virus infection in rhesus macaques AS Jaeger, CM Crooks, AM Weiler, MI Bliss, S Rybarczyk, A Richardson, ... Science Advances 9 (26), eadg3444, 2023 | | 2023 |
| Abstract B057: ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer SY Bae, HE Bergom, A Day, JT Greene, TS Freedman, JH Hwang, ... Cancer Research 83 (11_Supplement), B057-B057, 2023 | | 2023 |
| A dominant function of LynB kinase in preventing autoimmunity BFB IV, ML Sauer, JT Greene, SE Senevirathne, AJ Lindstedt, OL Funk, ... | | 2022 |
| The Par-4 Tumor Suppressor Protein in TCL1-Induced Leukemogenesis JT Greene, MK McKenna, S Bondada, N Muthusamy Tumor Suppressor Par-4: Role in Cancer and Other Diseases, 149-159, 2021 | | 2021 |
| Role of Par-4 in B-Cell Hematological Malignancies SK Noothi, MK McKenna, SS Alhakeem, JP Collard, JT Greene, ... Tumor Suppressor Par-4: Role in Cancer and Other Diseases, 133-148, 2021 | | 2021 |
| Investigation into the Role of the Par-4 Tumor Suppressor Pathway in B Cell Biology and Chronic Lymphocytic Leukemia JT Greene The Ohio State University, 2018 | | 2018 |
| Par-4 Overexpression Impedes Leukemogenesis in the Eµ-TCL1 Leukemia Model JT Greene, R Ramaswamy, MK McKenna, R Mani, F Frissora, R Wasmuth, ... Blood 130, 1223, 2017 | | 2017 |
Shuai DongJanssen Pharmaceutical Companies of Johnson & Johnson在 its.jnj.com 的电子邮件经过验证
Shuai DongJanssen Pharmaceutical Companies of Johnson & Johnson在 its.jnj.com 的电子邮件经过验证